Research Article

Clinically Relevant Solution for the Hypothermic Storage and Transportation of Human Multipotent Mesenchymal Stromal Cells

Yuriy Petrenko, Milada Chudickova, Irena Vackova, Tomas Groh, Eliska Kosnarova, Jitka Cejkova, Karolina Turnovcova, Alexander Petrenko, Eva Sykova, and Sarka Kubinova

1Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic
2Bioinova Ltd., Prague, Czech Republic
3Institute for Problems of Cryobiology and Cryomedicine, National Academy of Sciences of Ukraine, Kharkiv, Ukraine
4Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia

Correspondence should be addressed to Yuriy Petrenko; yuriy.petrenko@iem.cas.cz

Received 9 July 2018; Revised 6 October 2018; Accepted 23 October 2018; Published 20 January 2019

1. Introduction

Multipotent mesenchymal stromal cells (MSCs) are currently the most widely studied and applied cell type in regenerative medicine, with more than 700 registered clinical trials conducted worldwide (https://clinicaltrials.gov). High cell accessibility together with their unique paracrine and replacement properties drives the MSC research towards its translation into clinical practice [1, 2]. The clinical grade manufacturing process of MSCs comprises a number of regulated steps, aimed at assuring the safety and identity of the final cellular product. Many studies show different aspects of the clinical grade manufacturing of MSCs [3, 4]. The application of a chemically defined culture media, xeno-free supplements for in vitro expansion, and banking of MSCs are thoroughly discussed elsewhere [5, 6]. These studies provide key information for optimising the cell manufacturing process, to obtain safe and efficient cellular therapies.

Prior to clinical application, the safety and identity of the final MSC-based product must be confirmed by a panel of
techniques, recommended by the regulatory authorities. The absence of viral and microbial contamination, which may occur during isolation and in vitro cell expansion, represents the main aspect, confirming the safety of MSCs for clinical use. The microbiological quality control procedures must be defined and validated in each laboratory, according to the European Medicinal Agency guidelines and pharmacopoeia rules for parenteral medicinal products [7, 8]. Wherein, the final determination of sterility should be prepared prior to packaging (e.g., in the finished product), but in the event that the product would undergo cryopreservation, reseeding after thawing or any further manipulation requires repeated sterility testing [9]. Unfortunately, the fastest tests that are currently available require up to 48-72 hrs to obtain the results and any data obtained earlier are considered preliminary and insufficient. The Food and Drug Administration (FDA) has recently reported the suitability of several rapid tests for the fast (up to 72 hrs) detection of microorganisms in liquid media: BacT/ALERT® (bioMérieux), BACTEC™ (Becton Dickinson), and Rapid MilliFlex® from Merck Millipore [10]. However, even though rapid systems for contamination assessment are already available, such prolonged storage of cells, for 48-72 hrs in inappropriate conditions, would impact their viability and functional properties. Therefore, the search for optimal, reproducible storage conditions represents a critical issue in the cell manufacturing process, which lacks due consideration.

The hypothermic preservation in a nonfrozen state (at 2-8°C) represents the most reproducible and easy storage system; however, in incorrect conditions, it would lead to irreversible changes in cellular structure, leading to cell apoptosis and death. It is known that hypothermia causes the perturbation of ion balances, notably mono- and divalent cations (Na⁺, K⁺, and Ca²⁺) and anions (Cl⁻), which leads to osmotic cell swelling, oxidative stress, and an extracellular and intracellular pH switch [11, 12]. Thus, in ideal conditions, the vehicle solution for MSC administration should provide protection against these damaging factors. Conventional vehicle solutions for cell delivery in clinical settings usually represent either a simple physiological saline (e.g., Ringer’s solution for injections or 0.9% sodium chloride) or more complex electrolyte solutions (e.g., Plasma-Lyte® 148 or similar), which additionally may contain either human serum albumin or other nonionic plasma volume expanders (hydroxyethyl starch or dextran) [2]. However, the question regarding the applicability of such solutes for the hypothermic preservation of MSCs for 48 hrs–72 hrs should still be the subject of extensive research.

The application of specialised solutions developed for hypothermic preservation may represent an alternative way of optimising the storage conditions of cell-based products. Several widely used, commercially available solutions have been confirmed as effective for maintaining the viability of different cell types during cold storage [11, 13–16]. The University of Wisconsin Solution (UW solution) is considered as a gold standard medium for whole organ preservation. This highly effective complex solution, available on the market under the trademarks VIASPAN®, SPS-1® (Organ Recovery Systems, USA), and Belzer UW® Cold Storage Solution (Preservation Solutions Inc., USA), contains a large panel of components, which are aimed at providing an improved viability of organs prior to transplantation [12]. Several reports show its applicability for the hypothermic preservation of MSCs [17, 18]. However, the complex composition of this solution, which needs to be validated, according to clinical GMP standards for injectable devices, complicates its use as a vehicle solution for cell delivery proposes. HypoThermosol® FRS (HTS-FRS, BioLife Solutions, USA) represents another commercially available option for the storage of cells and tissues. The effective preservation has been confirmed for hepatocytes [13, 19], endothelial cells [13], MSCs monolayers [20], and neural stem cells [21]. The HTS-FRS solution is not yet approved by the regulatory authorities for direct administration to patients; nevertheless, several preclinical and clinical trials have already been carried out, using HTS-FRS as a vehicle solution for cell delivery (https://clinicaltrials.gov). It was shown that the application of HTS-FRS for low-volume intravenous injection of allogeneic equine cord blood-derived MSC suspensions was not associated with short-term adverse reactions [22].

Considering the limited number of available possibilities for the cold preservation of cell-based products, the development and optimisation of simple and efficient hypothermic storage solutions specifically for MSCs represents an important issue in regenerative medicine. We built our hypothesis on the idea that different cell types, which have distinct metabolic pathways and membrane transport parameters, would have a different resistance to the crucial factors that appear during the cold storage. It was previously shown that MSCs are more resistant to osmotic stresses, hypoxia, oxidative stress, or even ionizing radiation, compared to more differentiated cells [23–27]. Thus, it was assumed that the combination of the minimal number of essential components within the preservation medium, which are aimed at addressing the most crucial damaging factors that occurred during hypothermia, may be sufficient for maintaining the high viability and functional properties of MSCs and can be easily translated into a clinical-grade manufacturing process as a cell delivery vehicle solution.

In this study, we propose a simple and effective trehalose-based solution for the hypothermic storage of human bone marrow MSC suspensions. We have assessed the ability of this new solution to preserve the viability and functional properties of MSCs and compared its efficiency with other commercially available media.

2. Materials and Methods

2.1. The Isolation and Expansion of Human Bone Marrow MSCs. The research was approved by the ethical committee of the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic. Upon receipt of the informed consent from donors, who were either subjects in a clinical trial or undergoing orthopaedic surgery, human bone marrow (BM) was obtained from the iliac crest under local or general anaesthesia. To isolate MSCs, BM was applied on the perturbation of ion balances, notably mono- and divalent cations (Na⁺, K⁺, and Ca²⁺) and anions (Cl⁻), which leads to osmotic cell swelling, oxidative stress, and an extracellular and intracellular pH switch [11, 12]. Thus, in ideal conditions, the vehicle solution for MSC administration should provide protection against these damaging factors. Conventional vehicle solutions for cell delivery in clinical settings usually represent either a simple physiological saline (e.g., Ringer’s solution for injections or 0.9% sodium chloride) or more complex electrolyte solutions (e.g., Plasma-Lyte® 148 or similar), which additionally may contain either human serum albumin or other nonionic plasma volume expanders (hydroxyethyl starch or dextran) [2]. However, the question regarding the applicability of such solutes for the hypothermic preservation of MSCs for 48 hrs–72 hrs should still be the subject of extensive research.

The application of specialised solutions developed for hypothermic preservation may represent an alternative way of optimising the storage conditions of cell-based products. Several widely used, commercially available solutions have been confirmed as effective for maintaining the viability of different cell types during cold storage [11, 13–16]. The University of Wisconsin Solution (UW solution) is considered as a gold standard medium for whole organ preservation. This highly effective complex solution, available on the market under the trademarks VIASPAN®, SPS-1® (Organ Recovery Systems, USA), and Belzer UW® Cold Storage Solution (Preservation Solutions Inc., USA), contains a large panel of components, which are aimed at providing an improved viability of organs prior to transplantation [12]. Several reports show its applicability for the hypothermic preservation of MSCs [17, 18]. However, the complex composition of this solution, which needs to be validated, according to clinical GMP standards for injectable devices, complicates its use as a vehicle solution for cell delivery proposes. HypoThermosol® FRS (HTS-FRS, BioLife Solutions, USA) represents another commercially available option for the storage of cells and tissues. The effective preservation has been confirmed for hepatocytes [13, 19], endothelial cells [13], MSCs monolayers [20], and neural stem cells [21]. The HTS-FRS solution is not yet approved by the regulatory authorities for direct administration to patients; nevertheless, several preclinical and clinical trials have already been carried out, using HTS-FRS as a vehicle solution for cell delivery (https://clinicaltrials.gov). It was shown that the application of HTS-FRS for low-volume intravenous injection of allogeneic equine cord blood-derived MSC suspensions was not associated with short-term adverse reactions [22].

Considering the limited number of available possibilities for the cold preservation of cell-based products, the development and optimisation of simple and efficient hypothermic storage solutions specifically for MSCs represents an important issue in regenerative medicine. We built our hypothesis on the idea that different cell types, which have distinct metabolic pathways and membrane transport parameters, would have a different resistance to the crucial factors that appear during the cold storage. It was previously shown that MSCs are more resistant to osmotic stresses, hypoxia, oxidative stress, or even ionizing radiation, compared to more differentiated cells [23–27]. Thus, it was assumed that the combination of the minimal number of essential components within the preservation medium, which are aimed at addressing the most crucial damaging factors that occurred during hypothermia, may be sufficient for maintaining the high viability and functional properties of MSCs and can be easily translated into a clinical-grade manufacturing process as a cell delivery vehicle solution.

In this study, we propose a simple and effective trehalose-based solution for the hypothermic storage of human bone marrow MSC suspensions. We have assessed the ability of this new solution to preserve the viability and functional properties of MSCs and compared its efficiency with other commercially available media.
140,000 cells/cm², TPP Techno Plastic Products AG, Trasadingen, Switzerland) and allowed to adhere [28]. Nonadherent cells were removed after 24 and 48 hours by replacing the media. Adherent cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂ in MEM Alpha modification medium (Thermo Fisher Scientific Inc., USA, α-MEM) containing 5% of pooled platelet lysate (PL, Stemulate®, Cook Regentec, USA) and gentamicin (10 μg/ml; Gentamicin Lek®; Lek Pharmaceuticals, Ljubljana, Slovenia). The medium was changed twice a week. After reaching near-confluence, the cells were harvested by a TrypLE™ solution (Thermo Fisher Scientific Inc., USA). The cells were then seeded again onto a fresh plastic surface at the density 5 × 10⁵ cells/cm². MSCs from passages 2 to 4 have been used in this study.

2.2. The Hypothermic Storage of MSCs. The hypothermic storage of hMSC suspensions was prepared in a Buffers Trehalose Solution (BTS, prepared according to Czech Republic patent 306800) [29] and compared to several commercially available media: Ringer solution for infusion (Baxter Healthcare Ltd.), Plasma-Lyte® 148 (Baxter Healthcare Ltd.), and HypoThermosol® FRS (HTS-FRS, BioLife Solutions Inc.). BTS was prepared from cGMP-grade components (30 mM KH₂PO₄, 15 mM Na₂HPO₄, 0.5 mM CaCl₂, 1 mM MgSO₄, 250 mM trehalose, pH = 7.2, osmolarity = 300 – 350 mOsmol) [29]. Ringer’s and Plasma-Lyte® 148 were chosen as commonly used clinical grade vehicle solutions for cell delivery. HTS-FRS was used as a solution, which was reported to be efficient in the hypothermic preservation of tissues and different cell types.

For hypothermic storage, 10⁵ of harvested MSCs were resuspended in 1 mL of corresponding hypothermic storage solution, transferred into 1.8 mL cryovials (Nunc, USA), and placed at 4°C for 24 hrs, 48 hrs, and 72 hrs.

2.3. The Cell Viability, Recovery, and Proliferation of MSCs after Hypothermic Storage. The viability of MSCs before and after hypothermic storage was assessed using Trypan Blue plasma membrane integrity assay. Briefly, cell suspension was diluted 1:1 with 0.4% Trypan Blue solution (Sigma-Aldrich, USA) in PBS and counted in a Bürker haemocytometer, using standard protocol. The survival rate was expressed as a percentage of viable unstained cells in suspension, in relation to the total number of cells counted in a haemocytometer (n = 5).

The recovery of MSCs was assessed by the alamarBlue (AB) test [30, 31], using the same sample before and after hypothermic storage. Briefly, MSCs were resuspended in α-MEM, containing 5% PL, plated at a density of 2 × 10⁴ cells/cm² into standard 24-well plates (TPP, Switzerland), and cultured at 37°C, 5% CO₂, and 95% humidity. The recovery of MSCs was assessed after 24 hrs and 4 days of recultivation. MSCs were incubated for 3 hrs in a culture medium containing 10% AB. The fluorescence level of reduced AB was measured using a fluorescence intensity for each condition, after quantitative analysis using 9 reading lengths, using a multiple-point reading mode (9 reading points per well). The data were presented as an average of 9 readings.

2.4. Immunophenotypic Analysis. MSCs were harvested, counted, and characterised by flow cytometry. The cells were characterised by surface markers specific for MSCs [32]: major histocompatibility complex class I (MHC I; Exbio Ltd., Vestec, Czech Republic), CD90 and CD73 (BioLegend, San Diego, CA, USA) and CD105 (Exbio Ltd.), and low expression levels of CD34, HLAD-DR, and CD3 (Beckman Coulter Inc., Brea, CA, USA) and CD45, CD14, CD16, CD19, and CD80 (Exbio Ltd.). All antibodies were firstly titrated and used according to the manufacturer’s instructions. Briefly, cell pellets were washed with PBS and after spinning resuspended in PBS again. The cells were incubated in 50 μl of PBS containing specific antibodies for 15 min at room temperature. The cells were then washed with PBS, and 100,000 events were analysed using a FACSCanto II (BD, Franklin Lakes, NJ, USA) flow cytometer. The results were evaluated with FACSDiva Software (BD).

2.5. The Differentiation Properties of MSCs. The in vitro adipogenic and osteogenic differentiation capacity of MSCs after storage was assessed after seeding of the same amounts (2 × 10⁴/cm²) of viable cells into 24-well plates and additional expansion for 2-3 days in α-MEM, supplemented with 10% FBS.

The adipogenic differentiation medium consisted of α-MEM, supplemented with 10% FBS and the following adipogenic stimulants: 0.5 mM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, 10 μg/ml insulin, and 100 μM indomethacin (all from Sigma-Aldrich, USA). Complete medium changes were performed every 3-4 days. After 21 days of culture with adipogenic supplements, MSCs were fixed in a 4% buffered formalin solution for 30 min at 4°C and stained with a Nile Red (1 μg/ml in PBS) solution (Sigma-Aldrich, USA) according to the manufacturer’s instructions. The cells were assessed using a fluorescent microscope (Nikon, Japan). A quantitative assessment of the Nile Red fluorescence intensity in investigated groups was prepared in a microplate reader (Tecan Genios; Tecan, Austria) at 550 nm/590 nm wavelengths, using a multiple-point reading mode (9 reading points per well). The data were presented as an average of 9 readings.

The osteogenic differentiation medium consisted of α-MEM, supplemented with 10% FBS and osteogenic inducers: 0.2 mM ascorbic acid, 10 mM β-glycerophosphate, and 1 μM dexamethasone (all from Sigma-Aldrich, USA). Complete medium changes were performed every 3–4 days. Following 21 days of culture, MSCs were fixed in 4% buffered formalin for 30 min at 4°C. Matrix mineralization was assessed using alizarin red (Sigma-Aldrich, USA) staining for 10 min at room temperature. The quantitative analysis
of the osteogenic differentiation efficiency was performed by the assessment of calcium accumulation. After a 2 hr extraction of calcium from the cell culture vessels, using 0.1 N HCl, its content was assessed by the standard calcium biochemical assay kit (Erba Lachema Ltd., Czech Republic), according to the manufacturer’s instructions. The data were presented as Ca$^{2+}$ concentration (mg/l) after the subtraction of negative control values (obtained from noninduced cells).

2.6. The Immunomodulatory Properties of MSCs. The immunomodulatory properties of MSCs before and after 72 hrs of hypothermic storage were assessed by the ability of MSCs to suppress the phytohemagglutinin- (PHA-) induced proliferation of human peripheral blood mononuclear cells (PBMCs) in a direct coculture. PBMCs from at least 3 different human peripheral blood donors (obtained from the Institute of Hematology and Blood Transfusion, Prague, Czech Republic) were isolated by Ficoll-Paque (Miltenyi Biotec Inc., Germany, $\rho = 1.077$ g/ml) gradient centrifugation, according to the manufacturer’s instructions. For coculture experiments, $2 \times 10^5$ viable by Trypan Blue MSCs were seeded into separate wells of 96-well plates and treated with mitomycin C ($10 \mu g$/ml) for 2 hrs to arrest the cell proliferation. After 3 washes, MSCs were cultured for 24 hrs before the coculture experiment. Following 24 hrs of culture, the culture medium was discarded and $10^5$ PBMCs were seeded into each well (200 $\mu$l/well) in RPMI-1640 medium (Sigma-Aldrich), supplemented with 10% FBS (BIOSERA, France) and PHA (500x, Thermo Fisher Scientific Inc.). In each experiment, MSCs from at least 3 donors were cocultured with PBMCs from 3 donors. The final MSC to PBMC ratio comprised of 1:5. After 96 hrs of coculture, the proliferation of PBMCs was assessed by AB assay. Briefly, cells in each well were thoroughly resuspended and $100 \mu$l of nonadherent PBMCs were transferred into a fresh well of 96-well plates. $200 \mu$l of 10% AB solution was then added into each well, and the cells were incubated for 4 hrs at 37°C, 5% CO$_2$, and 95% humidity. The fluorescence level of the reduced AB index of PBMC proliferation was determined as a ratio in the control samples untreated by cytokines. Brieﬂy, MSC suspensions were divided into two parts. One part (around 2-5 $\times 10^6$ cells) was washed with PBS (1:10) and centrifuged at 2000 rpm for 10 min. Cell pellets were stored at -80°C for the following analysis. Additionally, $10^6$ of viable cells were seeded into T75 cell culture flasks (Nunc, USA) in serum-free α-MEM, containing an insulin-transferrin-selenium supplement (100x, Thermo Fisher Scientific Inc., USA), antibiotics, 5 ng/ml TNF-α, and 5 ng/ml IFN-γ. The cells were cultured at 37°C, 5% CO$_2$, and 95% humidity for 24 hrs, harvested by trypsinization, washed with PBS, and stored as cell pellets at -80°C for the following analysis. The changes in mRNA expression were determined in samples treated by cytokines by quantitative real-time PCR (qPCR) and plotted against the untreated controls. The RNA was isolated using the RNeasy Mini Kit (Roche, Germany), and RNA amounts were quantified using NanoPhotometer® P 330 (Implen, Germany). The isolated RNA was reverse-transcribed into complementary DNA using the Transcriptor Universal cDNA Master (Roche, Germany) and T100™ Thermal Cycler (Bio-Rad, USA). The qPCR reactions were performed using a cDNA solution, FastStart Universal Probe Master (Roche, Germany), and TaqMan® Gene Expression Assays (Thermo Fisher Scientific Inc., USA). The qPCR was carried out in a final volume of $10 \mu$l containing 65 ng of extracted RNA. The amplification was performed on the real-time PCR cycler (StepOnePlus™, Life Technologies, USA). All amplifications were run under the same cycling conditions: 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. All samples were run in duplicate, and a negative control (water) was included in each array. The results were expressed as log2-fold changes of ΔΔCt values, relative to the control samples untreated by cytokines.

2.8. Statistical Analysis. The experiments were performed from MSCs, obtained from 3 different donors in duplicate. The data are presented as mean ± SEM. The statistical analysis was prepared using the Mann-Whitney nonparametric test and considered significant with $p < 0.05$.

3. Results

3.1. The Viability and Recovery of MSCs after Hypothermic Storage. The viability of MSCs after 24 hrs of storage in Ringer’s solution falls dramatically and comprised of 42 ± 8% (Figure 1). The continuous cell storage resulted in a further decrease in cell viability, down to 22 ± 7% at 72 hrs. The viability of MSCs after hypothermic storage in Plasma-Lyte® 148 was significantly higher, compared to Ringers’ solution, at each investigated time point. After 72 hrs of storage in this solution, the viability of MSCs comprised of 41 ± 5% (Figure 1).

In contrast, the viability of MSCs after hypothermic storage in BTS or HTS-FRS was preserved after 72 hrs at significantly higher levels. The values were not significantly different between the groups and comprised of 78 ± 3% and 77 ± 2% for the HTS-FRS and BTS groups correspondingly (Figure 1).

The same situation was observed after the determination of cell recovery; however, the values were lower, compared to the viability (Figure 2).

The lowest cell recovery was obtained after 48 hrs and 72 hrs of storage in Ringer’s solution (23 ± 7% and 11 ± 8%, correspondingly). The recovery of MSCs stored for 48 hrs in Plasma-Lyte® 148, although being significantly higher
of MSCs comprised of about 80%, while after 72 hrs of storage the recovery rate decreased to 23 ± 2% after 72 hrs of hypothermic storage and subsequent utilization of the BTS or HTS-FRS for cell storage provides significantly higher compared to Plasma-Lyte® 148). However, the utilization of the BTS or HTS-FRS for cell storage provides high (more than 70%) viability and cell recovery, even after 72 hrs of hypothermic preservation.

3.2. The Immunophenotype of MSCs after Hypothermic Storage. To analyse whether the hypothermic storage conditions would affect the identity of MSCs, we studied the specific immunophenotype (Table 1) of MSCs after cold preservation in different conditions. The immunophenotypic analysis revealed that, independently of the duration of hypothermic preservation at 4°C and applied storage media, viable MSCs preserved their specific immunophenotype. More than 95% of viable cells had the immunophenotype CD105+/CD90+/CD73+/CD34−/CD45−/CD19−/CD14−/HLA-DR− which corresponded with the minimal criteria for multipotent mesenchymal stromal cells [32].

3.3. The Differentiation Properties of MSCs after Hypothermic Storage. The following assessment of the MSC capacity for induced differentiation towards adipogenic and osteogenic lineages was prepared by seeding the same amounts of viable MSCs and the following culture in differentiation media (Figure 3). The quantitative analysis of the differentiation efficiency did not reveal any significant differences between the applied hypothermic storage conditions, confirming the ability of MSCs to recover during prolonged in vitro culture (Figures 3(a) and 3(b)). Independently of the hypothermic storage conditions, the in vitro cell culture in the presence of specific inducers led to the accumulation of intracellular lipid droplets in adipogenic cultures (Figure 3(c)) and the appearance of a calcified matrix in osteogenic cultures, positively stained by alizarin red (Figure 3(d)). Chondrogenic differentiation was impaired after 72 hrs of hypothermic storage in Ringer’s solution and Plasma-Lyte® 148. In this case, no pellets were able to be formed due to the initially poor recovery of MSCs, stored in these conditions. This necessitates the additional expansion of MSCs after storage in saline solutions prior to application.

3.4. The Immunomodulatory Properties of MSCs after Hypothermic Storage. To reveal whether hypothermically stored MSCs preserved their immunomodulatory capacity, the cells were cocultured during 96 hrs with PHA-stimulated PBMCs. As shown in Figure 4, MSCs before and after 72 hrs of hypothermic storage in different preservation solutions were able to significantly suppress the PHA-induced proliferation of PBMCs in the direct coculture. Although the nonstored MSCs (fresh control) had a stronger influence on PBMC proliferation, the inhibitory activity of hypothermically stored MSCs had a similar tendency to the recovery rate, as previously observed. The most pronounced PBMC growth suppression was observed in the cocultures with MSCs, stored in BTS or HTS-FRS (Figure 4), being significantly stronger than the MSCs kept in Ringer’s solution.

The ability of stored MSCs to respond to inflammatory priming (IFN-γ and TNF-α stimulation) is another aspect, showing the therapeutic potential of MSCs prior to clinical application [33, 34]. In this study, the expression of genes involved in MSC immunomodulation (IDO-1, PD-L1, and IL-6) was assessed immediately after the storage in BTS and HTS-FRS (chosen as the most effective preserving media) and after 24 hrs in vitro stimulation with cytokines (Figure 5). Nonstored MSCs served as the control.
The levels of IDO-1, PD-L1, and IL-6 expression were significantly increased after IFN-γ and TNF-α stimulation confirming the preservation of the functional activity of MSCs after hypothermic storage. There were no significant differences in the response to proinflammatory factor stimulation between the nonpreserved cells and those after 72 hrs of hypothermic storage (Figure 5).

4. Discussion

In this study, we have compared the efficiency of the developed BTS with other commercially available solutions, regarding their ability to preserve the viability and functional properties of MSC suspensions during hypothermic storage. We tried to simulate real conditions, applied in biotechnological laboratories during the manufacturing of clinical-grade MSC-based products, and their preparation for further administration to the patient. To conduct the essential quality control analysis, the finally prepared MSC suspensions should be stored in a vehicle solution, which can be directly administered to a patient and which also provides the necessary protection to maintain the viability and identity of the cells.

We have assessed whether two commonly used saline solutions for injections (Ringer’s solution and Plasma-Lyte® 148) are able to provide the maintenance of essential cell functions during 1-3 days of hypothermic storage at 2-8°C. It was discovered that in contrast to Ringer’s solution, Plasma-Lyte® 148 can provide the survival of MSCs at about a 50% level after 48 hrs of storage; however, after 72 hrs of cold preservation, the recovery of cells was not higher than 25%. Nevertheless, the viable cells preserved their specific immunophenotype and capability for induced differentiation into adipogenic and osteogenic lineages. Previously, Chen et al. showed that cold (2-8°C) preservation in a 0.9% sodium chloride and Plasma-Lyte A solution already results in more than a 25% decrease in MSC attachment after 6 hrs of storage [35]. However, these values were higher compared to the same duration of storage at room temperature. Similar results have been shown by Pal et al., where the viability of MSCs after 8 hrs of storage at 4°C decreased to about 15% in Plasma-Lyte A, 0.9% saline solution, or Dulbecco’s phosphate-buffered saline [36]. The low efficiency of saline-based solutions, which were not specially formulated to preserve the viability of cells during hypothermic preservation, is also confirmed by several studies showing the cold storage of MSCs in a complete culture medium [37, 38].
Pogozhykh et al. showed less than 50% viability of placenta-derived MSCs after 48–72 hrs of storage in a culture medium at 4°C, additionally accompanied by a huge (5-10 times) drop of cell numbers, compared to the nonstored control [37]. Swioklo et al. showed only a 20% viable adipose tissue of MSC recovery after 72 hrs of hypothermic storage in a culture medium [38]. The low viability was also shown for MSCs stored at 4°C in the adherent state [18]. The authors could not detect any viable MSCs after 48 hrs of hypothermic preservation, either in a culture medium or in Hank’s balanced salt solution [18].

The change in cell ionic homeostasis which occurred under hypothermic conditions has been confirmed by many authors and thoroughly reviewed [11]. Hypothermic storage leads to a K+ loss from cells and is simultaneously accompanied by the intracellular diffusion of Na+ and Cl−, leading to a strong volume increase and cell swelling. Thus, one of the main reasons for low cell viability in standard saline-based solutions is more likely associated with the high amounts of sodium and chlorine ions in the preservation medium. Therefore, even these saline solutions are undoubtedly an optimal choice for the injection of fresh (nonstored) cells; they possess poor preservation potential during hypothermic storage. To reduce the cold-induced cell swelling, the partial substitution of these ions by nonpermeable, osmotically active components (e.g., saccharides) is a common option applied during the storage process.

**Figure 3**: Adipogenic (a, c) and osteogenic (b, d) differentiation of human MSCs after 72 hrs of hypothermic storage in different solutions and following recultivation. (a) Average Nile Red fluorescence intensity; (b) accumulated calcium content; (c) Nile red staining ×100; (d) alizarin red staining, ×100.

**Figure 4**: Proliferation of PHA-stimulated PBMC in coculture with MSCs before and after 72 hrs hypothermic storage in different preservation solutions. *Data is significantly different compared to MSC: PBMC coculture groups (p < 0.05); †data is significantly different compared to Ringer’s solution (p < 0.05); ‡values are significantly different compared to all coculture groups after 72 hrs of storage (p < 0.05).
development of specialised hypothermic storage solutions [11, 12, 16, 39, 40].

In our study, we developed a simple solution for the hypothermic storage of MSCs. Considering the high resistance of MSCs to various stress factors, we built our hypothesis on the basis that the essential functions of MSCs can be preserved using a simpler composition of the solution, providing stability of pH, close to physiological osmolarity, and preventing abnormal ion exchange and cell swelling. Such a hypothesis also seemed promising from a translational point of view: since all the components used for the preparation of the solution should be validated and each one may provide a negative action in vivo, the fewer number of chemicals in the mixture may simplify the use of such a medium as a vehicle solution for cell delivery. Previously, several modifications of different simple solutions, containing varying concentrations of sucrose and/or high molecular weight polyethylene glycol, BES, or

![Graphs showing gene expression analysis of MSCs after 72 hrs of hypothermic storage and following TNF-α/IFN-γ stimulation.](image)

**Figure 5:** Gene expression analysis of MSCs after 72 hrs of hypothermic storage and following TNF-α/IFN-γ stimulation.
other additives, have been shown to have a positive effect on the viability of hepatocytes [39, 41, 42], kidney cells [43], and endothelial cells [16] at cold storage conditions.

We have compared the efficiency of BTS with Hypothermosol® FRS, since this preservation medium was shown to have a confirmed positive impact on the survival of adherent MSCs [20]. According to available information [13, 44], the composition of a Hypothermosol® FRS solution is comprised of a specially formulated ionic mixture, pH buffers (including HEPES), several nonpermeable substances (sucrose, lactobionate, and mannitol), and adenosine and glutathione as metabolites. Overall, this composition provides the necessary defence for different cell types during hypothermic storage at 2-8°C [13, 19, 21]. We have determined that the preservation capacity of BTS is similar to HTS-FRS, since no significant differences were observed between these two solutions in all our experiments. Both solutions provided more than 70% recovery of MSCs, which could proliferate, differentiate, and suppress the proliferation of PBMCs in a coculture and respond to a proinflammatory cytokine stimulation in vitro, confirming the preservation of their therapeutically associated properties.

The BTS proposed in our study contains only 5 components, including inorganic pH buffers, and only one nonpermeable substance (trehalose) as a stabilising agent, providing balance in ion transport concentrations and protecting the cells against critical swelling. We chose trehalose in our study due to its confirmed ability to stabilise the phospholipid bilayers and labile proteins in mammalian cells [45–48] as well as reduce oxidative stress [49]. Trehalose is highly employed in cryopreservation studies as a nontoxic additive, capable of significantly reducing the concentration of permeable cryoprotectants (e.g., Me₂SO) or even excluding it from the freezing medium [2, 50, 51]. The positive effect of trehalose has been shown in ophthalmological studies to improve corneal regeneration after acute corneal damage [52] or dry eye syndrome [53]. We have previously shown that trehalose is a very potent therapeutic agent in corneal regeneration, which favourably influences the oxidative damage of the cornea and suppresses proinflammatory cytokine production [49, 52, 54]. Moreover, trehalose exhibits strong neuroprotective properties by stabilising proteins and significantly promoting autophagy [55, 56]. Recently, trehalose 90 mg/ml intravenous solution has received orphan drug designation from the Committee for Orphan Medicinal Products for treatment of spinocerebellar ataxia [57]. Moreover, the presence of trehalose in several commercially available products for topical (Thealoz®, Laboratoires Théa, Clermont-Ferrand, France) or injectable pharmaceutical therapeutics (e.g., Avastin®, Advate®, or Lucentis®) is promising for the future potential of using BTS or its modification as a vehicle solution for cell administration.

5. Conclusions

In this study, we have demonstrated the application of a simple buffered trehalose solution for the hypothermic storage of MSC suspensions with a high potential of translation into clinical practice. We found that the conventional vehicle solutions for cell administration cannot provide suitable viability of MSCs after hypothermic storage for 48-72 hrs, which may lead to nonsufficient therapeutic outcomes of MSC-based products in clinical trials. Subsequently, the BTS is capable of maintaining the viability and functional activity of MSCs for up to 3 days, which allows for the conduct of quality control analysis or transport prior to cell administration. The next stages of the study will be directed at preclinical and clinical studies, with the aim of confirming the safety of using BTS as a vehicle solution for cell delivery.

Data Availability

The data used to support the findings of this study are currently under embargo while the PCT patent application is under consideration. Requests for data, 12 months after publication of this article, will be considered by the corresponding author.

Disclosure

Part of this study was presented at TERMIS-EU meeting, Davos, 2017.

Conflicts of Interest

The PCT patent application has been submitted by the Institute of Experimental Medicine, Czech Academy of Sciences, and Bioinova Ltd: application number PCT/IB2017/052832.

Acknowledgments

This work was supported by the Grant Agency of the Czech Republic (GACR 17-03765S), MEYS of the Czech Republic (LO1309), EATRIS (LM2015064), and BIOCEV project (CZ.1.05/1.1.00/02.0109 BIOCEV, Czech Republic).

References

[1] F. G. Teixeira, M. M. Carvalho, N. Sousa, and A. J. Salgado, “Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?,” Cellular and Molecular Life Sciences, vol. 70, no. 20, pp. 3871–3882, 2013.
[2] L. A. Marquez-Curtis, A. Janowska-Wieczorek, L. E. McGann, and J. A. W. Elliott, “Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects,” Cryobiology, vol. 71, no. 2, pp. 181–197, 2015.
[3] A. Oikonomopoulos, W. K. Van Deen, A.-R. Manansala et al., “Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media,” Scientific Reports, vol. 5, no. 1, article 16570, 2015.
[4] P. Wuchter, K. Bieback, H. Schrenzenmeier et al., “Standardization of Good Manufacturing Practice–compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications,” Cytotherapy, vol. 17, no. 2, pp. 128–139, 2015.
[5] L. Sensebé, P. Bourin, and K. Tarte, “Good manufacturing practices production of mesenchymal stem/stromal cells,” Human Gene Therapy, vol. 22, no. 1, pp. 19–26, 2011.
[6] S. Thirumala, W. S. Goebel, and E. J. Woods, “Manufacturing and banking of mesenchymal stem cells,” Expert Opinion on Biological Therapy, vol. 13, no. 5, pp. 673–691, 2013.

[7] P. Galvez, B. Clares, M. Bermejo, A. Hmadcha, and B. Soria, “Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use,” Stem Cells and Development, vol. 23, no. 10, pp. 1074–1083, 2014.

[8] K. Coopman and N. Medcalf, "From production to patient: challenges and approaches for delivering cell therapies," in StemBook, pp. 1–11, Harvard Stem Cell Institute, Cambridge, MA, USA, 2014.

[9] “Questions and answers on allogenic stem cell-based products for veterinary use: specific questions on sterility,” https://www.ema.europa.eu/documents/scientific-guideline/questions-answers-allogenic-stem-cell-based-products-veterinary-use-specific-questions-sterility_en.pdf.

[10] S. Parveen, S. Kaur, S. A. David, J. L. Kenney, W. M. McCormick, and R. K. Gupta, “Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products,” Vaccine, vol. 29, no. 45, pp. 8012–8023, 2011.

[11] B. J. Fuller, A. Y. Petrenko, J. V. Rodriguez, A. Y. Somov, C. L. Balaban, and E. E. Guibert, “Biopreservation of hepatocytes: current concepts on hypothermic preservation, cryopreservation, and vitrification,” CryoLetters, vol. 34, no. 4, pp. 432–452, 2013.

[12] E. E. Guibert, A. Y. Petrenko, C. L. Balaban, A. Y. Somov, J. V. Rodriguez, and B. J. Fuller, “Organ preservation: current concepts and new strategies for the next decade,” Transfusion Medicine and Hemotherapy, vol. 38, no. 2, pp. 125–142, 2011.

[13] A. J. Mathew, J. M. Baust, R. G. Van Buskirk, and J. G. Baust, “Cell preservation in reparative and regenerative medicine: evolution of individualized solution composition,” Tissue Engineering, vol. 10, no. 11-12, pp. 1662–1671, 2004.

[14] I. C. J. H. Post, W. M. I. de Boon, M. Heger et al., “Endothelial cell preservation at hypothermic to normothermic conditions using clinical and experimental organ preservation solutions,” Experimental Cell Research, vol. 319, no. 17, pp. 2501–2513, 2013.

[15] B. J. Fuller, C. Shurey, N. Lane, A. Petrenko, and C. Green, “Hypothermic renal preservation with a sucrose/polyethylene glycol solution in a rabbit renal transplant model,” CryoLetters, vol. 27, no. 2, pp. 127–132, 2006.

[16] M. Hawkins, K. M. Sales, S. Dijk, and B. Fuller, “Cold preservation of endothelial cells in sucrose-based solution (SBS) and University of Wisconsin (UW) solutions: comparison of normoxic or hypoxic storage,” CryoLetters, vol. 26, no. 6, pp. 379–386, 2005.

[17] D. N. Tarusin, Y. A. Petrenko, O. A. Semchenko, V. V. Mutsenko, V. S. Zaikov, and A. Y. Petrenko, “Efficiency of the sucrose-based solution and UW solution for hypothermic storage of human mesenchymal stem cells in suspension or within alginate microspheres,” Problems of Cryobiology and Cryomedicine, vol. 25, no. 4, pp. 329–339, 2015.

[18] W. L. Corwin, J. M. Baust, J. G. Baust, and R. G. Van Buskirk, “Characterization and modulation of human mesenchymal stem cell stem cell pathway response following hypothermic storage,” Cryobiology, vol. 68, no. 2, pp. 215–226, 2014.

[19] A. Ostrowska, K. Gu, D. C. Bode, and R. G. van Buskirk, “Hypothermic storage of isolated human hepatocytes: a comparison between University of Wisconsin solution and a hypothermolos platform,” Archives of Toxicology, vol. 83, no. 5, pp. 493–502, 2009.

[20] I. Ginis, B. Grinblat, and M. H. Shirvan, “Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium,” Tissue Engineering Part C: Methods, vol. 18, no. 6, pp. 453–463, 2012.

[21] T. Rossetti, F. Nicholls, and M. Modo, “Intracerebral cell implantation: preparation and characterization of cell suspensions,” Cell Transplantation, vol. 25, no. 4, pp. 645–664, 2016.

[22] L. B. Williams, C. Co, J. B. Koenig, C. Tse, E. Lindsay, and T. G. Koch, “Response to intravenous allogeneic equine cord blood-derived mesenchymal stromal cells administered from chilled or frozen state in serum and protein-free media,” Frontiers in Veterinary Science, vol. 3, p. 56, 2016.

[23] B. Parekkadan, P. Sethu, D. van Poli, M. L. Yarmush, and M. Toner, “Osmotic selection of human mesenchymal stem/progenitor cells from umbilical cord blood,” Tissue Engineering, vol. 13, no. 10, pp. 2465–2473, 2007.

[24] N. H. Nicolay, R. Lopez Perez, R. Saffrich, and P. E. Huber, “Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic,” Oncotarget, vol. 6, no. 23, pp. 19366–19380, 2015.

[25] X. Xu, Y. Liu, Z. Cui, Y. Wei, and L. Zhang, “Effects of osmotic and cold shock on adherent human mesenchymal stem cells during cryopreservation,” Journal of Biotechnology, vol. 162, no. 2-3, pp. 224–231, 2012.

[26] L. B. Buravkova, E. R. Andreeva, V. Gogadze, and B. Zhivotovsky, “Mesenchymal stem cells and hypoxia: where are we?,” Mitochondrion, vol. 19, pp. 105–112, 2014.

[27] E. R. Andreeva, M. V. Lobanova, O. O. Udartseva, and L. B. Buravkova, “Response of adipose tissue-derived Stromal cells in tissue-related \( O_2 \) microenvironment to short-term hypoxic stress,” Cells Tissues Organs, vol. 200, no. 5, pp. 307–315, 2015.

[28] Z. Koci, K. Výborný, J. Dubísová et al., “Extracellular matrix hydrogel derived from human umbilical cord as a scaffold for neural tissue repair and its comparison with extracellular matrix from porcine tissues,” Tissue Engineering Part C: Methods, vol. 23, no. 6, pp. 333–345, 2017.

[29] Y. Petrenko, E. Syková, Č. Čejková, I. Vacková, and T. Groh, A Device for Storage, Transport and Application of Stem Cells, Institute of Experimental Medicine AS CR, 2017.

[30] S. N. Rampersad, “Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays,” Sensors, vol. 12, no. 9, pp. 12347–12360, 2012.

[31] Y. A. Petrenko, N. A. Gorokhova, E. N. Tkachova, and A. Y. Petrenko, “The reduction of Alamur Blue by peripheral blood lymphocytes and isolated mitochondria,” Ukrainskii Biokhimicheskii Zhurnal, vol. 77, no. 5, pp. 100–105, 2005.

[32] M. Dominici, K. L. Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.

[33] E. Amati, S. Sella, O. Perbellini et al., “Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use,” Stem Cell Research & Therapy, vol. 8, no. 1, p. 14, 2017.

[34] S. Ma, N. Xie, W. Li, B. Yuan, Y. Shi, and Y. Wang, “Immunobiology of mesenchymal stem cells,” Cell Death & Differentiation, vol. 21, no. 2, pp. 216–225, 2014.
[35] Y. Chen, B. Yu, G. Xue et al., "Effects of storage solutions on the viability of human umbilical cord mesenchymal stem cells for transplantation," Cell Transplantation, vol. 22, no. 6, pp. 1075–1086, 2013.

[36] R. Pal, M. Hanwate, and S. M. Totey, "Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow-derived mesenchymal stem cells before transplantation," Journal of Tissue Engineering and Regenerative Medicine, vol. 2, no. 7, pp. 436–444, 2008.

[37] D. Pogozhykh, V. Prokopyyuk, O. Pogozhykh, T. Mueller, and O. Prokopyyuk, "Influence of factors of cryopreservation and hypothermic storage on survival and functional parameters of multipotent stromal cells of placental origin," PLoS One, vol. 10, no. 10, article e0139834, 2015.

[38] S. Swioklo, A. Constantinescu, and C. J. Connor, "Alginate-encapsulation for the improved hypothermic preservation of human adipose-derived stem cells," Stem Cells Translational Medicine, vol. 5, no. 3, pp. 339–349, 2016.

[39] I. V. Shanina, L. P. Kravchenko, B. J. Fuller, and V. I. Grischenko, "A comparison of a sucrose-based solution with other preservation media for cold storage of isolated hepatocytes," Cryobiology, vol. 41, no. 4, pp. 315–318, 2000.

[40] G. Di, J. Wang, M. Liu, C. T. Wu, Y. Han, and H. Duan, "Development and evaluation of a trehalose-contained solution formula to preserve hUC-MSCs at 4°C," Journal of Cellular Physiology, vol. 227, no. 3, pp. 879–884, 2012.

[41] L. P. Kravchenko, A. Y. Petrenko, A. Y. Somov, V. I. Grischenko, and B. J. Fuller, "Respiratory activity of isolated rat hepatocytes following cold storage and subsequent rewarming: a comparison of sucrose-based and University of Wisconsin solutions," Cryobiology, vol. 42, no. 3, pp. 218–221, 2001.

[42] M. E. Mamprin, S. Petrocelli, E. Guibert, and J. Rodriguez, "A novel BES-glucosamine-sucrose (BGS) solution for cold storage of isolated hepatocytes," CryoLetters, vol. 29, no. 2, pp. 121–133, 2008.

[43] M. Katayama, S. Tsuchiaka, T. Motegi et al., "High-molecular-weight polyethylene glycol enhances hypothermic storage of feline kidney cells," The Journal of Veterinary Medical Science, vol. 76, no. 6, pp. 923–926, 2014.

[44] J. M. Baust, R. Van Buskirk, and J. G. Baust, "Modulation of the cryopreservation cap: elevated survival with reduced dimethyl sulfoxide concentration," Cryobiology, vol. 45, no. 2, pp. 97–108, 2002.

[45] J. Luycx and C. Baudouin, "Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology," Clinical Ophthalmology, vol. 5, pp. 577–581, 2011.

[46] A. D. Elbein, Y. T. Pan, I. Pastuszak, and D. Carroll, "New insights on trehalose: a multifunctional molecule," Glycobiology, vol. 13, no. 4, pp. 17R–27R, 2003.

[47] M. Hovakimyan, T. Ramoth, M. Lobler et al., "Evaluation of protective effects of trehalose on desiccation of epithelial cells in three dimensional reconstructed human corneal epithelium," Current Eye Research, vol. 37, no. 11, pp. 982–989, 2012.

[48] A. Hill-Bator, M. Misik-Hojo, K. Marycz, and J. Grzesiak, "Trehalose-based eye drops preserve viability and functionality of cultured human corneal epithelial cells during desiccation," BioMed Research International, vol. 2014, Article ID 292139, 8 pages, 2014.

[49] J. Čejková, T. Ardan, Č. Čejka, and J. Luycx, "Favorable effects of trehalose on the development of UVB-mediated antioxidant/pro-oxidant imbalance in the corneal epithelium, proinflammatory cytokine and matrix metalloproteinase induction, and heat shock protein 70 expression," Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 8, pp. 1185–1194, 2011.

[50] Y. A. Petrenko, O. Y. Rogul'ska, V. V. Mutsenko, and A. Y. Petrenko, "A sugar pretreatment as a new approach to the Me2SO- and xeno-free cryopreservation of human mesenchymal stromal cells," CryoLetters, vol. 35, no. 3, pp. 239–246, 2014.

[51] H. Huang, G. Zhao, Y. Zhang, J. Xu, T. L. Toth, and X. He, "Predehydration and ice seeding in the presence of trehalose enable cell cryopreservation," ACS Biomaterials Science & Engineering, vol. 3, no. 8, pp. 1758–1768, 2017.

[52] J. Čejková, Č. Čejka, T. Ardan, J. Širc, J. Michálek, and J. Luycx, "Reduced UVB-induced corneal damage caused by reactive oxygen and nitrogen species and decreased changes in corneal optics after trehalose treatment," Histology and Histopathology, vol. 25, no. 11, pp. 1403–1416, 2010.

[53] A. J. Mateo Orobia, P. C. Pascual, J. Á. Cristobal Bescós et al., "Effects of 3% trehalose as an adjuvant treatment after LASIK," Clinical Ophthalmology, vol. 11, pp. 347–353, 2017.

[54] J. Čejková, Č. Čejka, and J. Luycx, "Trehalose treatment accelerates the healing of UVB-irradiated corneas. Comparative immunohistochemical studies on corneal cryostat sections and corneal impression cytology," Histology and Histopathology, vol. 27, no. 8, pp. 1029–1040, 2012.

[55] E. Emanuele, "Can trehalose prevent neurodegeneration? Insights from experimental studies," Current Drug Targets, vol. 15, no. 5, pp. 551–557, 2014.

[56] M. J. Casarejos, R. M. Solano, A. Gomez, J. Perucho, J. G. de Yebenes, and M. A. Mena, "The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells," Neurochemistry International, vol. 58, no. 4, pp. 512–520, 2011.

[57] "Public summary of opinion on orphan designation. Trehalose for the treatment of spino-cerebellar ataxia," https://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/07/WC500190623.pdf.